About: TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.20 (-6.01%)
TCRX NASDAQ Tscan Therapeutics Inc
Tscan Therapeutics Inc share price
Atividade de preço de TCRX
Último preço
$ 0,200
Variação (24h)
-0,01 USD (6,01%)
Volume
262.78K
Volume (média 4 sem.)
-
Abertura
$ 0,23
Variação do dia
$ 0,20 - $ 0,23
Fechamento anterior
$ 0,22
Último negócio
23 Oct, 8:01 pm GMT+0
Atrasado
23 Oct, 8:01 pm GMT+0
TCRX price performance
Atrasado
23 Oct, 8:01 pm GMT+0
quote.marketSignals